{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"105"}]}],"title":"AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"31"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","groups":[{"description":"Participants received an oral dose of 45 milligram (mg) of MEK162 tablets (3 tablets of 15 mg) twice daily for each 28-day treatment cycle until disease progression, withdrawal of consent, initiation of subsequent anticancer therapy, lost to follow-up or death, whichever occurred first. Participants were followed up to 30 days after last dose of study intervention.","id":"OG000","title":"MEK162"},{"description":"Participants received chemotherapies as per treating physician's choice in accordance to the institutional standard of care. Participants received one of the three intravenous (IV) infusion therapies: Liposomal doxorubicin 40 milligram per meter square (mg/m\\^2) on Day 1 of each 28-day cycle or Paclitaxel 80 mg/m\\^2 on Days 1, 8, and 15 of each 28-day cycle or, Topotecan 1.25 mg/m\\^2 on Days 1 through 5 of each 21-day cycle. Participants were followed up to 30 days after last dose of study intervention.","id":"OG001","title":"Physician's Choice"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety set included all participants who received at least 1 dose of study intervention and had at least 1 post-treatment assessment, including death. No data was collected for the crossover set due to the early stopping of the crossover period.","reportingStatus":"POSTED","timeFrame":"From the first dose of study intervention until 30 days after the last dose (up to 9 years)","title":"Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}